sales@angenesci.com
Login | Register
logo
Structures Search
Home Other Building Blocks RO4929097

RO4929097

CAS No.:
847925-91-1
Catalog Number:
AG003ACA
Molecular Formula:
C22H20F5N3O3
Molecular Weight:
469.4045
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
1mg
≥98%
1 week
United States
$125
- +
5mg
98%
1 week
United States
$196
- +
10mg
98%
1 week
United States
$307
- +
50mg
98%
1 week
United States
$835
- +
100mg
98%
1 week
United States
$1515
- +
Product Description
Catalog Number:
AG003ACA
Chemical Name:
RO4929097
CAS Number:
847925-91-1
Molecular Formula:
C22H20F5N3O3
Molecular Weight:
469.4045
MDL Number:
MFCD18384976
IUPAC Name:
2,2-dimethyl-N-[(7S)-6-oxo-5,7-dihydrobenzo[d][1]benzazepin-7-yl]-N'-(2,2,3,3,3-pentafluoropropyl)propanediamide
InChI:
InChI=1S/C22H20F5N3O3/c1-20(2,18(32)28-11-21(23,24)22(25,26)27)19(33)30-16-14-9-4-3-7-12(14)13-8-5-6-10-15(13)29-17(16)31/h3-10,16H,11H2,1-2H3,(H,28,32)(H,29,31)(H,30,33)/t16-/m0/s1
InChI Key:
OJPLJFIFUQPSJR-INIZCTEOSA-N
SMILES:
O=C1Nc2ccccc2c2c([C@@H]1NC(=O)C(C(=O)NCC(C(F)(F)F)(F)F)(C)C)cccc2
UNII:
KK8645V7LE
Properties
Complexity:
771  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
1  
Defined Bond Stereocenter Count:
0
Exact Mass:
469.142g/mol
Formal Charge:
0
Heavy Atom Count:
33  
Hydrogen Bond Acceptor Count:
8  
Hydrogen Bond Donor Count:
3  
Isotope Atom Count:
0
Molecular Weight:
469.412g/mol
Monoisotopic Mass:
469.142g/mol
Rotatable Bond Count:
5  
Topological Polar Surface Area:
87.3A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
4.6  
Literature
Title Journal
Identification of potent Yes1 kinase inhibitors using a library screening approach. Bioorganic & medicinal chemistry letters 20130801
Phase I study of RO4929097, a gamma secretase inhibitor of Notch signaling, in patients with refractory metastatic or locally advanced solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20120701
Initial testing (stage 1) by the pediatric preclinical testing program of RO4929097, a γ-secretase inhibitor targeting notch signaling. Pediatric blood & cancer 20120501
A phase II study of RO4929097 in metastatic colorectal cancer. European journal of cancer (Oxford, England : 1990) 20120501
High tumor levels of IL6 and IL8 abrogate preclinical efficacy of the γ-secretase inhibitor, RO4929097. Molecular oncology 20110601
Validation and implementation of a liquid chromatography/tandem mass spectrometry assay for quantitation of the total and unbound RO4929097, a γ-secretase inhibitor targeting Notch signaling, in human plasma. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20110601
The novel gamma secretase inhibitor RO4929097 reduces the tumor initiating potential of melanoma. PloS one 20110101
Preclinical profile of a potent gamma-secretase inhibitor targeting notch signaling with in vivo efficacy and pharmacodynamic properties. Cancer research 20091001
Properties